Molecular docking studies indicate that seven representative compounds of XQLD exhibit favorable binding properties to NLRP3, potentially inhibiting NLRP3 inflammasome-mediated pyroptosis in nasal mucosa and improving allergic rhinitis symptoms (132). This evidence concerns the gene NLRP3 and allergic rhinitis.